Physician profile
Mandissa Sealey
NPI 1760870778
$1,601.35
in general payments reported to CMS, 2019-2025
29 companies · $394 in 2025
The $394 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $58.62 · 2021: $201 · 2022: $214 · 2023: $319 · 2024: $415 · 2025: $394.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,128.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,127.92 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mylan Specialty L.P. | $217.31 | 2021-2024 | Yupelri |
| Novartis Pharmaceuticals Corporation | $184.85 | 2022-2025 | |
| Lilly USA, LLC | $138.71 | 2021-2025 | Mounjaro, Jardiance |
| Novo Nordisk INC | $116.74 | 2019-2025 | Wegovy, Rybelsus, Ozempic |
| Abbvie INC. | $95.64 | 2021-2025 | Vraylar |
| Amgen INC. | $83.70 | 2023-2025 | Repatha, Otezla, Evenity |
| Astrazeneca Pharmaceuticals LP | $83.46 | 2021-2025 | Airsupra, Farxiga |
| Glaxosmithkline, LLC. | $79.48 | 2019-2024 | Trelegy Ellipta, Shingrix |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $74.64 | 2024-2025 | Caplyta |
| Amarin Pharma, INC. | $69.64 | 2021-2022 | |
| Viatris Specialty LLC | $49.09 | 2025 | Yupelri |
| Boehringer Ingelheim Pharmaceuticals, INC. | $40.00 | 2021-2022 | |
| Vanda Pharmaceuticals INC. | $35.72 | 2024-2025 | Fanapt |
| Janssen Pharmaceuticals, INC | $35.50 | 2023-2024 | Xarelto |
| Shield Therapeutics INC | $32.10 | 2024 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $32.07 | 2024-2025 | Rexulti |
| Verona Pharma, INC. | $27.83 | 2025 | Ohtuvayre |
| Teva Pharmaceuticals USA, INC. | $26.20 | 2022 | |
| Almatica Pharma LLC | $22.18 | 2025 | Loreev Xr |
| Sumitomo Pharma America, INC. | $18.68 | 2025 | Gemtesa |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $18.21 | 2021 | |
| Idorsia Pharmaceuticals US INC | $18.06 | 2023 | Quviviq |
| Astellas Pharma US INC | $15.62 | 2021 | |
| Phathom Pharmaceuticals, INC. | $15.22 | 2025 | Voquezna |
| Radius Health, INC. | $15.20 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $15.17 | 2023 | |
| Covis Pharma Gmbh | $14.87 | 2022 | |
| Exact Sciences Corporation | $13.96 | 2025 | The Cologuard Plus Collection Kit |
| Horizon Therapeutics Plc | $11.50 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mandissa Sealey listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.